A study by Agawa et al. demonstrated that intravitreal anti-VEGF treatment (with bevacizumab) itself significantly raised intraocular levels of IL-6 and IL-8 [45], both implicated in AMD pathogenesis. This evidence concerns the gene VEGFA and age-related macular degeneration.